Mass. Firm to Appeal $431M Damages for Stent Patent Infringement
A jury says Boston Scientific Corp. must pay $431 million in damages in a patent dispute over the medical device maker’s drug-coated stents.
The company said that federal jury in Marshall, Texas reached the damages award in a patent infringement lawsuit brought by Dr. Bruce Saffran. The jury found that Boston Scientific’s Taxus Express and Taxus Liberte stents infringe on a patent that Saffran holds.
Boston Scientific argues the verdict is unsupported by evidence and the law. The Natick, Massachusetts-based company plans to try to overturn the verdict in post-trial motions. If that’s unsuccessful, Boston Scientific says it will appeal.
Stents are tiny, mesh-wire tubes that prop open arteries after they have been surgically cleared of fatty plaque.
- Bodily Injury Is Now A Big Share of Auto Claims Payouts. Is AI to Blame for That Too?
- Cost of a Data Breach Reaches Record $5 Million on Average
- Major Hedge Funds Targeted in Wave of Attempted Cyberattacks
- AI Skills More Valuable Than MBAs, 86% of Finance Executives Say